 Nanette Santoro
Concepts (910)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menopause | 88 | 2023 | 271 | 17.180 |
Why?
| | Infertility, Female | 44 | 2023 | 94 | 8.540 |
Why?
| | Women's Health | 41 | 2023 | 271 | 6.420 |
Why?
| | Hot Flashes | 31 | 2023 | 72 | 6.300 |
Why?
| | Estrogen Replacement Therapy | 29 | 2023 | 116 | 6.000 |
Why?
| | Follicle Stimulating Hormone | 61 | 2022 | 216 | 5.840 |
Why?
| | Perimenopause | 24 | 2022 | 61 | 5.570 |
Why?
| | Luteinizing Hormone | 54 | 2022 | 169 | 5.220 |
Why?
| | Estradiol | 56 | 2024 | 455 | 5.130 |
Why?
| | Menstrual Cycle | 33 | 2023 | 108 | 5.120 |
Why?
| | Polycystic Ovary Syndrome | 33 | 2022 | 141 | 5.120 |
Why?
| | Endocrinology | 9 | 2023 | 70 | 4.860 |
Why?
| | Postmenopause | 33 | 2020 | 303 | 4.100 |
Why?
| | Anti-Mullerian Hormone | 16 | 2023 | 50 | 4.000 |
Why?
| | Infertility | 13 | 2024 | 45 | 3.880 |
Why?
| | Reproductive Medicine | 8 | 2023 | 15 | 3.700 |
Why?
| | Ovary | 23 | 2024 | 191 | 3.520 |
Why?
| | Estrogens | 22 | 2024 | 312 | 3.300 |
Why?
| | Female | 328 | 2024 | 59573 | 3.070 |
Why?
| | Progesterone | 37 | 2023 | 232 | 3.000 |
Why?
| | Ovulation Induction | 29 | 2022 | 49 | 2.770 |
Why?
| | Primary Ovarian Insufficiency | 13 | 2021 | 30 | 2.760 |
Why?
| | Fertilization in Vitro | 18 | 2024 | 71 | 2.740 |
Why?
| | Androgens | 15 | 2021 | 167 | 2.640 |
Why?
| | Obesity | 29 | 2022 | 2508 | 2.630 |
Why?
| | Metabolic Syndrome | 14 | 2021 | 321 | 2.590 |
Why?
| | Luteal Phase | 16 | 2020 | 41 | 2.530 |
Why?
| | Hormones | 12 | 2021 | 132 | 2.460 |
Why?
| | Humans | 348 | 2024 | 114711 | 2.430 |
Why?
| | Reproduction | 8 | 2022 | 178 | 2.310 |
Why?
| | Fertility | 14 | 2022 | 130 | 2.150 |
Why?
| | Aging | 26 | 2024 | 1618 | 2.110 |
Why?
| | Adult | 181 | 2024 | 30562 | 2.020 |
Why?
| | Endometrium | 15 | 2020 | 60 | 1.930 |
Why?
| | Testosterone | 24 | 2021 | 343 | 1.900 |
Why?
| | Ovulation | 14 | 2018 | 39 | 1.870 |
Why?
| | Live Birth | 20 | 2022 | 48 | 1.850 |
Why?
| | Ovarian Follicle | 10 | 2024 | 61 | 1.830 |
Why?
| | Fertility Agents, Female | 14 | 2022 | 19 | 1.830 |
Why?
| | Menopause, Premature | 4 | 2021 | 8 | 1.810 |
Why?
| | Gonadal Steroid Hormones | 13 | 2024 | 124 | 1.800 |
Why?
| | Cardiovascular Diseases | 22 | 2024 | 1728 | 1.690 |
Why?
| | Estrogens, Conjugated (USP) | 12 | 2023 | 34 | 1.640 |
Why?
| | Hormone Replacement Therapy | 9 | 2022 | 77 | 1.640 |
Why?
| | Sexual Dysfunction, Physiological | 9 | 2018 | 60 | 1.620 |
Why?
| | Quality of Life | 17 | 2023 | 2353 | 1.580 |
Why?
| | Depression | 12 | 2019 | 1135 | 1.570 |
Why?
| | Infertility, Male | 11 | 2022 | 59 | 1.540 |
Why?
| | Carotid Intima-Media Thickness | 10 | 2021 | 65 | 1.460 |
Why?
| | Middle Aged | 116 | 2024 | 26740 | 1.440 |
Why?
| | Pregnancy | 64 | 2024 | 5520 | 1.420 |
Why?
| | Biomarkers | 31 | 2022 | 3408 | 1.370 |
Why?
| | Body Mass Index | 34 | 2022 | 1959 | 1.360 |
Why?
| | Amenorrhea | 12 | 2017 | 27 | 1.360 |
Why?
| | Vagina | 3 | 2020 | 146 | 1.360 |
Why?
| | Gonadotropin-Releasing Hormone | 16 | 2022 | 188 | 1.360 |
Why?
| | Pregnanediol | 10 | 2020 | 12 | 1.360 |
Why?
| | Vasomotor System | 8 | 2021 | 39 | 1.310 |
Why?
| | Pregnancy Rate | 20 | 2022 | 55 | 1.290 |
Why?
| | Vaginal Diseases | 3 | 2020 | 17 | 1.280 |
Why?
| | Estrone | 11 | 2024 | 35 | 1.270 |
Why?
| | Endocrinologists | 3 | 2023 | 12 | 1.270 |
Why?
| | Hypothalamus | 10 | 2014 | 147 | 1.270 |
Why?
| | Premenopause | 13 | 2022 | 106 | 1.230 |
Why?
| | Double-Blind Method | 29 | 2023 | 1660 | 1.210 |
Why?
| | Hormone Antagonists | 2 | 2021 | 33 | 1.210 |
Why?
| | Inhibins | 8 | 2018 | 45 | 1.190 |
Why?
| | Embryo Transfer | 10 | 2024 | 29 | 1.190 |
Why?
| | Atherosclerosis | 6 | 2024 | 341 | 1.180 |
Why?
| | Gynecology | 2 | 2021 | 163 | 1.170 |
Why?
| | Receptors, Neurokinin-3 | 3 | 2023 | 6 | 1.120 |
Why?
| | Endometriosis | 4 | 2022 | 40 | 1.110 |
Why?
| | Anovulation | 7 | 2015 | 8 | 1.090 |
Why?
| | Cryopreservation | 5 | 2024 | 92 | 1.090 |
Why?
| | Hyperlipidemias | 5 | 2022 | 121 | 1.090 |
Why?
| | Uterus | 4 | 2019 | 192 | 1.060 |
Why?
| | Prospective Studies | 42 | 2024 | 6220 | 1.040 |
Why?
| | Sleep Wake Disorders | 6 | 2021 | 233 | 1.030 |
Why?
| | Patient Selection | 7 | 2021 | 641 | 1.010 |
Why?
| | Hyperinsulinism | 3 | 2022 | 103 | 1.000 |
Why?
| | Insulin | 11 | 2022 | 2082 | 1.000 |
Why?
| | Clomiphene | 9 | 2021 | 15 | 0.990 |
Why?
| | Aromatase Inhibitors | 3 | 2020 | 49 | 0.980 |
Why?
| | Randomized Controlled Trials as Topic | 19 | 2023 | 1214 | 0.970 |
Why?
| | Mental Health | 2 | 2022 | 561 | 0.950 |
Why?
| | HIV Infections | 17 | 2024 | 2469 | 0.940 |
Why?
| | Biomedical Research | 4 | 2023 | 585 | 0.920 |
Why?
| | Sex Hormone-Binding Globulin | 14 | 2020 | 48 | 0.920 |
Why?
| | Follicle Stimulating Hormone, Human | 3 | 2022 | 11 | 0.910 |
Why?
| | Salpingo-oophorectomy | 1 | 2024 | 11 | 0.900 |
Why?
| | United States | 49 | 2023 | 12184 | 0.890 |
Why?
| | Longitudinal Studies | 25 | 2020 | 2387 | 0.890 |
Why?
| | Life Cycle Stages | 1 | 2023 | 32 | 0.890 |
Why?
| | Menarche | 2 | 2017 | 49 | 0.860 |
Why?
| | Gonadotropins | 5 | 2020 | 37 | 0.850 |
Why?
| | Aromatase | 3 | 2014 | 30 | 0.830 |
Why?
| | Hypothalamo-Hypophyseal System | 5 | 2017 | 164 | 0.830 |
Why?
| | Progestins | 4 | 2017 | 75 | 0.830 |
Why?
| | Drug Compounding | 3 | 2021 | 89 | 0.810 |
Why?
| | Ovarian Reserve | 3 | 2020 | 13 | 0.810 |
Why?
| | Sexual Health | 1 | 2023 | 46 | 0.810 |
Why?
| | Lipids | 7 | 2023 | 580 | 0.810 |
Why?
| | Irritable Mood | 3 | 2018 | 48 | 0.810 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2021 | 1183 | 0.800 |
Why?
| | Treatment Outcome | 35 | 2023 | 9089 | 0.800 |
Why?
| | Pituitary Gland | 6 | 2021 | 148 | 0.790 |
Why?
| | Sleep Initiation and Maintenance Disorders | 4 | 2018 | 119 | 0.770 |
Why?
| | Age Factors | 22 | 2023 | 2894 | 0.760 |
Why?
| | Corpus Luteum | 7 | 2017 | 19 | 0.750 |
Why?
| | Administration, Cutaneous | 12 | 2023 | 117 | 0.750 |
Why?
| | Hydrocortisone | 4 | 2022 | 267 | 0.750 |
Why?
| | Embryo, Mammalian | 1 | 2022 | 213 | 0.740 |
Why?
| | Soybean Oil | 1 | 2021 | 12 | 0.740 |
Why?
| | Fetal Research | 1 | 2021 | 3 | 0.740 |
Why?
| | Research Subjects | 1 | 2021 | 40 | 0.740 |
Why?
| | Federal Government | 1 | 2021 | 26 | 0.740 |
Why?
| | Cross-Sectional Studies | 30 | 2022 | 4411 | 0.730 |
Why?
| | Hand Strength | 1 | 2021 | 96 | 0.730 |
Why?
| | Bicycling | 1 | 2021 | 86 | 0.730 |
Why?
| | Adolescent | 47 | 2021 | 17856 | 0.710 |
Why?
| | Sleep | 9 | 2021 | 632 | 0.710 |
Why?
| | Ultrasonography | 6 | 2018 | 634 | 0.710 |
Why?
| | Symptom Assessment | 2 | 2021 | 119 | 0.700 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2021 | 151 | 0.700 |
Why?
| | Risk Factors | 46 | 2024 | 8634 | 0.690 |
Why?
| | Reproductive Health | 3 | 2023 | 71 | 0.680 |
Why?
| | Longevity | 1 | 2021 | 137 | 0.680 |
Why?
| | Premature Birth | 3 | 2022 | 276 | 0.680 |
Why?
| | Obstetrics | 1 | 2021 | 146 | 0.680 |
Why?
| | Young Adult | 32 | 2022 | 10472 | 0.670 |
Why?
| | Phospholipids | 1 | 2021 | 197 | 0.660 |
Why?
| | Practice Guidelines as Topic | 3 | 2016 | 1394 | 0.660 |
Why?
| | Hypogonadism | 8 | 2015 | 75 | 0.650 |
Why?
| | Cohort Studies | 28 | 2023 | 4895 | 0.640 |
Why?
| | Spatial Memory | 1 | 2019 | 17 | 0.630 |
Why?
| | Sexuality | 1 | 2018 | 19 | 0.630 |
Why?
| | Hysterosalpingography | 1 | 2018 | 6 | 0.630 |
Why?
| | Hypothalamic Diseases | 3 | 2017 | 17 | 0.620 |
Why?
| | Ovarian Hyperstimulation Syndrome | 3 | 2008 | 6 | 0.620 |
Why?
| | Life Style | 10 | 2024 | 429 | 0.600 |
Why?
| | Insemination, Artificial | 5 | 2022 | 12 | 0.570 |
Why?
| | Substance-Related Disorders | 6 | 2009 | 947 | 0.570 |
Why?
| | Heterocyclic Compounds, 2-Ring | 3 | 2023 | 4 | 0.570 |
Why?
| | Circadian Rhythm | 3 | 2017 | 356 | 0.550 |
Why?
| | Health Surveys | 5 | 2011 | 443 | 0.550 |
Why?
| | Fetus | 1 | 2021 | 700 | 0.550 |
Why?
| | Hysterectomy | 5 | 2023 | 106 | 0.540 |
Why?
| | Hypopituitarism | 2 | 2014 | 15 | 0.540 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2011 | 256 | 0.530 |
Why?
| | Cognition | 10 | 2022 | 989 | 0.530 |
Why?
| | Overweight | 5 | 2014 | 472 | 0.530 |
Why?
| | Pregnancy Trimester, First | 2 | 2019 | 125 | 0.520 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2016 | 26 | 0.520 |
Why?
| | Chorionic Gonadotropin | 9 | 2021 | 78 | 0.520 |
Why?
| | Adiposity | 4 | 2020 | 458 | 0.520 |
Why?
| | Surveys and Questionnaires | 20 | 2022 | 4624 | 0.520 |
Why?
| | Cumulus Cells | 2 | 2015 | 6 | 0.510 |
Why?
| | Levonorgestrel | 1 | 2015 | 31 | 0.510 |
Why?
| | Sweating | 4 | 2018 | 23 | 0.500 |
Why?
| | Uterine Hemorrhage | 3 | 2021 | 34 | 0.500 |
Why?
| | Tandem Mass Spectrometry | 2 | 2015 | 412 | 0.500 |
Why?
| | Insemination, Artificial, Heterologous | 1 | 2015 | 2 | 0.490 |
Why?
| | Azoospermia | 1 | 2015 | 5 | 0.490 |
Why?
| | Abortion, Spontaneous | 6 | 2021 | 90 | 0.490 |
Why?
| | Anxiety | 4 | 2018 | 840 | 0.480 |
Why?
| | Bone Density | 7 | 2011 | 432 | 0.480 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 90 | 0.460 |
Why?
| | Body Composition | 9 | 2024 | 590 | 0.460 |
Why?
| | Pulsatile Flow | 3 | 2011 | 54 | 0.460 |
Why?
| | Nitriles | 5 | 2015 | 149 | 0.460 |
Why?
| | Vulvodynia | 1 | 2014 | 2 | 0.460 |
Why?
| | Granulosa Cells | 4 | 2021 | 29 | 0.460 |
Why?
| | Time Factors | 19 | 2024 | 6114 | 0.450 |
Why?
| | Indoles | 1 | 2016 | 304 | 0.450 |
Why?
| | Cross-Over Studies | 4 | 2022 | 440 | 0.450 |
Why?
| | Triazoles | 5 | 2015 | 131 | 0.440 |
Why?
| | Pregnancy Outcome | 9 | 2021 | 337 | 0.440 |
Why?
| | Blood Proteins | 1 | 2015 | 231 | 0.440 |
Why?
| | Osteoporosis | 1 | 2016 | 226 | 0.420 |
Why?
| | Pregnancy, Multiple | 4 | 2015 | 14 | 0.420 |
Why?
| | Insulin Resistance | 9 | 2023 | 1072 | 0.420 |
Why?
| | Stress, Psychological | 8 | 2018 | 944 | 0.410 |
Why?
| | Solubility | 2 | 2023 | 223 | 0.410 |
Why?
| | Male | 62 | 2022 | 55669 | 0.400 |
Why?
| | Complementary Therapies | 3 | 2022 | 72 | 0.400 |
Why?
| | Parity | 2 | 2011 | 98 | 0.400 |
Why?
| | Follicular Phase | 12 | 2014 | 36 | 0.400 |
Why?
| | Insemination, Artificial, Homologous | 3 | 2021 | 3 | 0.400 |
Why?
| | Cell Cycle | 1 | 2015 | 542 | 0.400 |
Why?
| | Prevalence | 13 | 2019 | 2251 | 0.390 |
Why?
| | Prolactin | 4 | 2022 | 96 | 0.390 |
Why?
| | Follow-Up Studies | 16 | 2023 | 4411 | 0.390 |
Why?
| | Plaque, Atherosclerotic | 2 | 2024 | 44 | 0.380 |
Why?
| | Intracranial Thrombosis | 1 | 2011 | 17 | 0.380 |
Why?
| | Weight Gain | 5 | 2020 | 453 | 0.370 |
Why?
| | Menstruation | 9 | 2012 | 35 | 0.370 |
Why?
| | Fallopian Tubes | 3 | 2018 | 29 | 0.370 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2008 | 256 | 0.370 |
Why?
| | Endocrine System | 1 | 2011 | 19 | 0.370 |
Why?
| | Thyrotropin | 3 | 2022 | 99 | 0.370 |
Why?
| | Pregnancy, Ectopic | 3 | 2021 | 51 | 0.370 |
Why?
| | Exercise | 3 | 2022 | 1644 | 0.370 |
Why?
| | Coronary Artery Disease | 4 | 2019 | 607 | 0.360 |
Why?
| | Uterine Diseases | 2 | 2007 | 14 | 0.360 |
Why?
| | Methotrexate | 4 | 2021 | 226 | 0.350 |
Why?
| | Thiadiazoles | 2 | 2020 | 21 | 0.350 |
Why?
| | Logistic Models | 14 | 2015 | 1841 | 0.350 |
Why?
| | Abortifacient Agents, Nonsteroidal | 2 | 2021 | 19 | 0.340 |
Why?
| | Prognosis | 14 | 2020 | 3330 | 0.340 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2021 | 32 | 0.340 |
Why?
| | Activins | 3 | 2005 | 26 | 0.340 |
Why?
| | Watchful Waiting | 2 | 2021 | 55 | 0.340 |
Why?
| | Regression Analysis | 7 | 2020 | 945 | 0.340 |
Why?
| | Odds Ratio | 14 | 2015 | 953 | 0.330 |
Why?
| | Oocyte Donation | 1 | 2009 | 4 | 0.330 |
Why?
| | Signal Transduction | 3 | 2021 | 4517 | 0.330 |
Why?
| | Multicenter Studies as Topic | 8 | 2022 | 249 | 0.330 |
Why?
| | Vulva | 1 | 2009 | 24 | 0.330 |
Why?
| | Breast Neoplasms | 4 | 2022 | 1862 | 0.320 |
Why?
| | Trinucleotide Repeats | 1 | 2009 | 24 | 0.320 |
Why?
| | Administration, Oral | 8 | 2020 | 729 | 0.320 |
Why?
| | Hyperandrogenism | 4 | 2017 | 14 | 0.320 |
Why?
| | Multivariate Analysis | 13 | 2015 | 1430 | 0.320 |
Why?
| | Fertility Agents | 2 | 2020 | 2 | 0.320 |
Why?
| | Luteal Cells | 1 | 2008 | 2 | 0.320 |
Why?
| | Semen | 4 | 2022 | 18 | 0.320 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2009 | 51 | 0.310 |
Why?
| | Ovariectomy | 3 | 2023 | 116 | 0.310 |
Why?
| | Pituitary Hormone-Releasing Hormones | 6 | 1989 | 10 | 0.310 |
Why?
| | Adaptation, Psychological | 3 | 2018 | 547 | 0.310 |
Why?
| | Mentors | 1 | 2010 | 156 | 0.310 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 668 | 0.310 |
Why?
| | Administration, Intravaginal | 2 | 2020 | 20 | 0.300 |
Why?
| | Aged | 21 | 2023 | 19075 | 0.300 |
Why?
| | Carotid Artery Diseases | 2 | 2020 | 57 | 0.300 |
Why?
| | Vitamin D Deficiency | 2 | 2021 | 158 | 0.300 |
Why?
| | Bone Remodeling | 2 | 2008 | 65 | 0.300 |
Why?
| | Mood Disorders | 3 | 2015 | 112 | 0.300 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 53 | 0.300 |
Why?
| | Risk Assessment | 12 | 2024 | 2968 | 0.300 |
Why?
| | Incidence | 8 | 2020 | 2314 | 0.300 |
Why?
| | Metformin | 3 | 2012 | 276 | 0.290 |
Why?
| | Oocyte Retrieval | 3 | 2015 | 11 | 0.290 |
Why?
| | Polyps | 1 | 2007 | 11 | 0.290 |
Why?
| | Leiomyoma | 2 | 2019 | 44 | 0.290 |
Why?
| | Vitamin D | 3 | 2021 | 341 | 0.290 |
Why?
| | Pericardium | 3 | 2019 | 50 | 0.280 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2023 | 245 | 0.280 |
Why?
| | Virilism | 1 | 2007 | 5 | 0.280 |
Why?
| | Antioxidants | 2 | 2021 | 530 | 0.280 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 130 | 0.280 |
Why?
| | Lactation | 1 | 2008 | 149 | 0.270 |
Why?
| | Dehydroepiandrosterone Sulfate | 6 | 2011 | 45 | 0.270 |
Why?
| | Fertilization | 3 | 2022 | 41 | 0.270 |
Why?
| | Reproductive Techniques | 3 | 2001 | 6 | 0.270 |
Why?
| | Cytokines | 3 | 2021 | 1841 | 0.270 |
Why?
| | Pilot Projects | 5 | 2020 | 1373 | 0.270 |
Why?
| | Metabolome | 1 | 2009 | 282 | 0.270 |
Why?
| | Affect | 3 | 2018 | 246 | 0.270 |
Why?
| | Weight Loss | 5 | 2024 | 642 | 0.270 |
Why?
| | Inflammation | 3 | 2022 | 2480 | 0.260 |
Why?
| | Specimen Handling | 3 | 2018 | 156 | 0.260 |
Why?
| | Attitude to Health | 3 | 2009 | 406 | 0.260 |
Why?
| | Bariatric Surgery | 1 | 2008 | 161 | 0.260 |
Why?
| | Cholesterol, LDL | 2 | 2010 | 307 | 0.250 |
Why?
| | Case-Control Studies | 7 | 2020 | 3004 | 0.250 |
Why?
| | New York City | 6 | 2010 | 70 | 0.250 |
Why?
| | Leuprolide | 4 | 1998 | 19 | 0.250 |
Why?
| | Oxidative Stress | 2 | 2021 | 1076 | 0.250 |
Why?
| | Contraceptive Agents, Female | 2 | 2016 | 64 | 0.240 |
Why?
| | Atrophy | 2 | 2020 | 152 | 0.240 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3256 | 0.240 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 501 | 0.240 |
Why?
| | Socioeconomic Factors | 7 | 2013 | 1079 | 0.240 |
Why?
| | Age of Onset | 3 | 2017 | 446 | 0.240 |
Why?
| | Dehydroepiandrosterone | 5 | 2016 | 49 | 0.240 |
Why?
| | Recovery of Function | 1 | 2008 | 574 | 0.240 |
Why?
| | C-Reactive Protein | 4 | 2022 | 362 | 0.240 |
Why?
| | Follistatin | 1 | 2004 | 12 | 0.240 |
Why?
| | Biology | 2 | 2023 | 79 | 0.230 |
Why?
| | Academic Medical Centers | 4 | 2021 | 411 | 0.230 |
Why?
| | Vascular Calcification | 2 | 2019 | 107 | 0.230 |
Why?
| | Adipose Tissue | 3 | 2019 | 545 | 0.230 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 932 | 0.230 |
Why?
| | Embryo Culture Techniques | 1 | 2024 | 12 | 0.230 |
Why?
| | Skin Aging | 2 | 2016 | 19 | 0.220 |
Why?
| | Insulin-Like Growth Factor I | 4 | 2022 | 286 | 0.220 |
Why?
| | Child | 22 | 2023 | 18423 | 0.220 |
Why?
| | Fractures, Bone | 2 | 2008 | 367 | 0.220 |
Why?
| | Oligomenorrhea | 2 | 2014 | 6 | 0.210 |
Why?
| | Drug Therapy, Combination | 5 | 2018 | 951 | 0.210 |
Why?
| | Bone Resorption | 2 | 2015 | 73 | 0.210 |
Why?
| | Endometrial Hyperplasia | 1 | 2023 | 10 | 0.210 |
Why?
| | Cell Cycle Proteins | 1 | 2007 | 551 | 0.210 |
Why?
| | Reference Values | 8 | 2020 | 743 | 0.210 |
Why?
| | Interleukin-6 | 2 | 2022 | 676 | 0.210 |
Why?
| | Carotid Stenosis | 1 | 2024 | 79 | 0.210 |
Why?
| | National Institute of Child Health and Human Development (U.S.) | 2 | 2023 | 8 | 0.210 |
Why?
| | Dyspareunia | 2 | 2016 | 8 | 0.210 |
Why?
| | Diabetes Mellitus | 3 | 2023 | 900 | 0.210 |
Why?
| | Animals | 14 | 2023 | 31710 | 0.210 |
Why?
| | Anti-HIV Agents | 2 | 2005 | 666 | 0.210 |
Why?
| | Dilatation and Curettage | 2 | 2021 | 10 | 0.210 |
Why?
| | Referral and Consultation | 3 | 2016 | 635 | 0.210 |
Why?
| | Asymptomatic Diseases | 3 | 2018 | 75 | 0.210 |
Why?
| | Goals | 1 | 2023 | 147 | 0.200 |
Why?
| | Smoking | 6 | 2015 | 1383 | 0.200 |
Why?
| | Reimbursement Mechanisms | 2 | 2001 | 77 | 0.200 |
Why?
| | Simvastatin | 1 | 2002 | 59 | 0.200 |
Why?
| | Cuba | 3 | 2010 | 11 | 0.200 |
Why?
| | Human Growth Hormone | 1 | 2022 | 38 | 0.200 |
Why?
| | Central America | 3 | 2010 | 16 | 0.200 |
Why?
| | Puerto Rico | 3 | 2010 | 51 | 0.190 |
Why?
| | South America | 3 | 2010 | 52 | 0.190 |
Why?
| | Washington | 1 | 2022 | 134 | 0.190 |
Why?
| | Germ Cells | 1 | 2022 | 57 | 0.190 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 73 | 0.190 |
Why?
| | Ankle Brachial Index | 1 | 2021 | 30 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3053 | 0.190 |
Why?
| | Health Behavior | 1 | 2007 | 703 | 0.190 |
Why?
| | Semen Analysis | 4 | 2022 | 10 | 0.190 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 141 | 0.190 |
Why?
| | Urologic Surgical Procedures, Male | 2 | 2011 | 27 | 0.190 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 28 | 0.180 |
Why?
| | Emulsions | 1 | 2021 | 42 | 0.180 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2021 | 27 | 0.180 |
Why?
| | Sexual Behavior | 3 | 2016 | 440 | 0.180 |
Why?
| | Cell Proliferation | 2 | 2009 | 2187 | 0.180 |
Why?
| | Biomarkers, Tumor | 1 | 2007 | 1040 | 0.180 |
Why?
| | Linear Models | 7 | 2019 | 768 | 0.180 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 238 | 0.180 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 207 | 0.180 |
Why?
| | Thinness | 1 | 2021 | 87 | 0.180 |
Why?
| | Drug Combinations | 3 | 2016 | 287 | 0.180 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2021 | 91 | 0.180 |
Why?
| | Genetic Fitness | 1 | 2021 | 54 | 0.180 |
Why?
| | RNA, Messenger | 6 | 2011 | 2553 | 0.180 |
Why?
| | Heat-Shock Proteins | 1 | 2021 | 113 | 0.180 |
Why?
| | Glucose Clamp Technique | 1 | 2021 | 181 | 0.180 |
Why?
| | Spermatozoa | 3 | 2022 | 84 | 0.170 |
Why?
| | Dominican Republic | 2 | 2010 | 18 | 0.170 |
Why?
| | Obesity, Abdominal | 2 | 2022 | 37 | 0.170 |
Why?
| | Vitamins | 1 | 2021 | 151 | 0.170 |
Why?
| | Coitus | 2 | 2022 | 27 | 0.170 |
Why?
| | Choice Behavior | 1 | 2021 | 155 | 0.170 |
Why?
| | Lipoproteins, HDL | 3 | 2015 | 75 | 0.170 |
Why?
| | Electronics | 1 | 2000 | 67 | 0.170 |
Why?
| | Ethics, Medical | 1 | 2000 | 70 | 0.170 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 162 | 0.170 |
Why?
| | Down-Regulation | 5 | 2019 | 594 | 0.170 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 165 | 0.170 |
Why?
| | Puberty | 2 | 2019 | 135 | 0.170 |
Why?
| | Gene Expression | 3 | 2021 | 1421 | 0.170 |
Why?
| | Growth Hormone | 2 | 2022 | 103 | 0.170 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2011 | 36 | 0.170 |
Why?
| | Leptin | 3 | 2022 | 210 | 0.170 |
Why?
| | Surgeons | 1 | 2023 | 239 | 0.160 |
Why?
| | Gonadotropins, Pituitary | 4 | 2011 | 22 | 0.160 |
Why?
| | Adiponectin | 3 | 2022 | 213 | 0.160 |
Why?
| | Erectile Dysfunction | 1 | 2019 | 38 | 0.160 |
Why?
| | Cell Nucleolus | 2 | 2010 | 17 | 0.160 |
Why?
| | Acculturation | 2 | 2010 | 50 | 0.160 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2015 | 801 | 0.160 |
Why?
| | Spermatogenesis | 1 | 2019 | 52 | 0.160 |
Why?
| | Decidua | 1 | 2019 | 23 | 0.160 |
Why?
| | Insulin-Like Growth Factor Binding Protein 1 | 1 | 2019 | 24 | 0.160 |
Why?
| | Sperm Count | 4 | 2022 | 16 | 0.160 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 12 | 0.160 |
Why?
| | Carotid Arteries | 1 | 2020 | 180 | 0.160 |
Why?
| | Allostasis | 1 | 2018 | 12 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 250 | 0.150 |
Why?
| | Ovarian Diseases | 3 | 1993 | 12 | 0.150 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 38 | 0.150 |
Why?
| | Infant, Newborn | 9 | 2024 | 5048 | 0.150 |
Why?
| | Waist Circumference | 5 | 2022 | 122 | 0.150 |
Why?
| | Precision Medicine | 1 | 2022 | 337 | 0.150 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 373 | 0.150 |
Why?
| | Decision Support Techniques | 1 | 2022 | 355 | 0.150 |
Why?
| | Adrenal Glands | 1 | 1998 | 66 | 0.150 |
Why?
| | Genitalia | 1 | 2018 | 28 | 0.150 |
Why?
| | Child Behavior | 1 | 2020 | 219 | 0.150 |
Why?
| | Periodicity | 8 | 2016 | 55 | 0.150 |
Why?
| | Placebos | 2 | 2015 | 197 | 0.150 |
Why?
| | Keratin-18 | 1 | 2017 | 10 | 0.140 |
Why?
| | Religion | 1 | 2018 | 64 | 0.140 |
Why?
| | Comorbidity | 5 | 2014 | 1448 | 0.140 |
Why?
| | Clinical Protocols | 1 | 2018 | 233 | 0.140 |
Why?
| | Disease Progression | 4 | 2020 | 2382 | 0.140 |
Why?
| | Brachial Artery | 1 | 2018 | 176 | 0.140 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2017 | 20 | 0.140 |
Why?
| | Phytotherapy | 1 | 2017 | 66 | 0.140 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2017 | 27 | 0.140 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 740 | 0.140 |
Why?
| | Models, Biological | 5 | 2016 | 1621 | 0.140 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 103 | 0.140 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 185 | 0.140 |
Why?
| | Body Weight | 4 | 2015 | 869 | 0.130 |
Why?
| | Retrospective Studies | 12 | 2024 | 12558 | 0.130 |
Why?
| | Receptors, Leptin | 2 | 2013 | 24 | 0.130 |
Why?
| | Regional Blood Flow | 1 | 2018 | 424 | 0.130 |
Why?
| | Microbiota | 1 | 2024 | 647 | 0.130 |
Why?
| | Antidepressive Agents | 1 | 2018 | 195 | 0.130 |
Why?
| | Heart | 1 | 2020 | 612 | 0.130 |
Why?
| | Infant | 15 | 2024 | 7969 | 0.130 |
Why?
| | Vaginal Creams, Foams, and Jellies | 1 | 2016 | 6 | 0.130 |
Why?
| | Orgasm | 1 | 2016 | 6 | 0.130 |
Why?
| | Uterine Neoplasms | 1 | 2017 | 73 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1518 | 0.130 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2016 | 28 | 0.130 |
Why?
| | Oxytocics | 1 | 2016 | 15 | 0.130 |
Why?
| | Health Status | 3 | 2023 | 722 | 0.130 |
Why?
| | Child Development | 1 | 2020 | 385 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 1356 | 0.130 |
Why?
| | Fetal Growth Retardation | 2 | 2019 | 468 | 0.130 |
Why?
| | Societies, Scientific | 1 | 2016 | 47 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1177 | 0.130 |
Why?
| | Endocrine System Diseases | 1 | 2016 | 30 | 0.130 |
Why?
| | Causality | 2 | 2014 | 103 | 0.130 |
Why?
| | Fluoroimmunoassay | 2 | 1999 | 3 | 0.130 |
Why?
| | Confidence Intervals | 4 | 2011 | 305 | 0.130 |
Why?
| | Chromatography, Liquid | 2 | 2015 | 347 | 0.130 |
Why?
| | Societies, Medical | 3 | 2017 | 664 | 0.130 |
Why?
| | Oxytocin | 1 | 2016 | 45 | 0.130 |
Why?
| | Chlamydia trachomatis | 1 | 2015 | 36 | 0.130 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 90 | 0.130 |
Why?
| | Hirsutism | 2 | 2017 | 10 | 0.120 |
Why?
| | Intrauterine Devices, Medicated | 1 | 2015 | 23 | 0.120 |
Why?
| | Stress, Physiological | 1 | 2018 | 378 | 0.120 |
Why?
| | Body Constitution | 3 | 2004 | 47 | 0.120 |
Why?
| | Vasodilation | 1 | 2018 | 419 | 0.120 |
Why?
| | Mobility Limitation | 1 | 2015 | 60 | 0.120 |
Why?
| | Patient Dropouts | 1 | 2015 | 66 | 0.120 |
Why?
| | Air Pollution | 1 | 2017 | 169 | 0.120 |
Why?
| | Drug Approval | 1 | 2015 | 78 | 0.120 |
Why?
| | Migraine Disorders | 1 | 2016 | 82 | 0.120 |
Why?
| | Limit of Detection | 1 | 2015 | 53 | 0.120 |
Why?
| | Adaptation, Physiological | 1 | 2018 | 483 | 0.120 |
Why?
| | Depressive Disorder, Major | 1 | 2018 | 301 | 0.120 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2015 | 64 | 0.120 |
Why?
| | Antibodies, Bacterial | 1 | 2015 | 119 | 0.120 |
Why?
| | Survival Analysis | 4 | 2014 | 1211 | 0.120 |
Why?
| | Chlamydia Infections | 1 | 2015 | 65 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2021 | 800 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 172 | 0.120 |
Why?
| | Contraindications | 1 | 2014 | 85 | 0.120 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 281 | 0.120 |
Why?
| | Immunoglobulin G | 2 | 2015 | 770 | 0.120 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 1796 | 0.120 |
Why?
| | Physical Fitness | 1 | 2015 | 179 | 0.120 |
Why?
| | Laparoscopy | 1 | 2018 | 398 | 0.120 |
Why?
| | Cellular Microenvironment | 1 | 2015 | 78 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2015 | 6346 | 0.110 |
Why?
| | Arthritis, Psoriatic | 1 | 2014 | 16 | 0.110 |
Why?
| | Creatinine | 3 | 2022 | 425 | 0.110 |
Why?
| | Child, Preschool | 15 | 2020 | 9119 | 0.110 |
Why?
| | Sperm Motility | 3 | 2022 | 26 | 0.110 |
Why?
| | Fatigue | 1 | 2015 | 294 | 0.110 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 314 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1140 | 0.110 |
Why?
| | Oocytes | 2 | 2011 | 170 | 0.110 |
Why?
| | Bone Marrow Transplantation | 4 | 1999 | 239 | 0.110 |
Why?
| | Range of Motion, Articular | 1 | 2015 | 350 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2015 | 455 | 0.110 |
Why?
| | Liver | 3 | 2023 | 1637 | 0.110 |
Why?
| | Autoimmunity | 1 | 1999 | 813 | 0.110 |
Why?
| | Muscle Strength | 1 | 2015 | 271 | 0.110 |
Why?
| | Methadone | 2 | 2011 | 77 | 0.100 |
Why?
| | Rats | 3 | 2019 | 4959 | 0.100 |
Why?
| | Anxiety Disorders | 1 | 2015 | 303 | 0.100 |
Why?
| | Chi-Square Distribution | 4 | 2015 | 493 | 0.100 |
Why?
| | Heart Rate | 1 | 2016 | 709 | 0.100 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2012 | 6 | 0.100 |
Why?
| | Epithelial Cells | 2 | 2009 | 951 | 0.100 |
Why?
| | Drug Administration Schedule | 2 | 2012 | 718 | 0.100 |
Why?
| | Heart Diseases | 1 | 2015 | 331 | 0.100 |
Why?
| | China | 4 | 2011 | 161 | 0.100 |
Why?
| | Varicocele | 1 | 2011 | 10 | 0.100 |
Why?
| | Skin | 1 | 2016 | 655 | 0.100 |
Why?
| | Placenta Diseases | 1 | 2011 | 13 | 0.100 |
Why?
| | Tissue Banks | 1 | 2011 | 17 | 0.100 |
Why?
| | Receptors, Somatomedin | 1 | 2011 | 3 | 0.100 |
Why?
| | Receptors, Glucagon | 1 | 2011 | 23 | 0.100 |
Why?
| | Somatomedins | 1 | 2011 | 28 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2015 | 515 | 0.100 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2320 | 0.090 |
Why?
| | Glucagon | 1 | 2011 | 92 | 0.090 |
Why?
| | Pregnancy Complications | 2 | 2015 | 429 | 0.090 |
Why?
| | Receptor, trkA | 1 | 2011 | 16 | 0.090 |
Why?
| | Narcotics | 1 | 2011 | 44 | 0.090 |
Why?
| | Algorithms | 3 | 2011 | 1470 | 0.090 |
Why?
| | Siblings | 2 | 2009 | 221 | 0.090 |
Why?
| | Autoantibodies | 1 | 1999 | 1349 | 0.090 |
Why?
| | Actigraphy | 3 | 2017 | 75 | 0.090 |
Why?
| | Glucose | 2 | 2007 | 897 | 0.090 |
Why?
| | Pelvic Organ Prolapse | 1 | 2011 | 39 | 0.090 |
Why?
| | CD4 Lymphocyte Count | 3 | 2006 | 257 | 0.090 |
Why?
| | Protease Inhibitors | 1 | 2011 | 97 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2017 | 489 | 0.090 |
Why?
| | Skin Physiological Phenomena | 1 | 2010 | 26 | 0.090 |
Why?
| | Japan | 3 | 2011 | 86 | 0.090 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2010 | 7 | 0.090 |
Why?
| | Fetal Diseases | 1 | 2011 | 147 | 0.090 |
Why?
| | Superovulation | 3 | 2012 | 8 | 0.090 |
Why?
| | Hip Fractures | 1 | 2011 | 75 | 0.090 |
Why?
| | Decision Trees | 1 | 2010 | 81 | 0.090 |
Why?
| | Environment | 2 | 2003 | 332 | 0.090 |
Why?
| | Proteomics | 1 | 2015 | 837 | 0.080 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2011 | 351 | 0.080 |
Why?
| | Blood Glucose | 5 | 2019 | 1828 | 0.080 |
Why?
| | Career Mobility | 1 | 2010 | 61 | 0.080 |
Why?
| | Minisatellite Repeats | 1 | 2009 | 38 | 0.080 |
Why?
| | Health Promotion | 1 | 2015 | 687 | 0.080 |
Why?
| | Comprehension | 1 | 2011 | 156 | 0.080 |
Why?
| | Lithium Chloride | 1 | 2009 | 11 | 0.080 |
Why?
| | Glucocorticoids | 1 | 1993 | 532 | 0.080 |
Why?
| | Quality Control | 2 | 2000 | 144 | 0.080 |
Why?
| | Memory | 1 | 2011 | 211 | 0.080 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 220 | 0.080 |
Why?
| | Blastocyst | 1 | 2009 | 44 | 0.080 |
Why?
| | HIV Seropositivity | 2 | 2011 | 109 | 0.080 |
Why?
| | Perception | 1 | 2011 | 310 | 0.080 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 2 | 1999 | 14 | 0.080 |
Why?
| | Sleep Apnea Syndromes | 1 | 2009 | 74 | 0.080 |
Why?
| | Autoimmune Diseases | 2 | 2003 | 382 | 0.080 |
Why?
| | Vaginitis | 1 | 2008 | 2 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 1842 | 0.080 |
Why?
| | Birth Weight | 2 | 2024 | 440 | 0.080 |
Why?
| | Nuclear Pore | 1 | 2008 | 14 | 0.080 |
Why?
| | Osteoprotegerin | 1 | 2008 | 23 | 0.080 |
Why?
| | Embryo Implantation | 1 | 2008 | 23 | 0.080 |
Why?
| | Wounds and Injuries | 1 | 2015 | 749 | 0.080 |
Why?
| | Coronary Disease | 2 | 2012 | 348 | 0.080 |
Why?
| | Uterine Prolapse | 1 | 2008 | 11 | 0.070 |
Why?
| | Social Class | 1 | 2009 | 204 | 0.070 |
Why?
| | Infant, Low Birth Weight | 2 | 2019 | 125 | 0.070 |
Why?
| | Analysis of Variance | 4 | 2019 | 1226 | 0.070 |
Why?
| | Androstenedione | 2 | 1999 | 10 | 0.070 |
Why?
| | Anthropometry | 1 | 2008 | 183 | 0.070 |
Why?
| | Self Report | 3 | 2018 | 696 | 0.070 |
Why?
| | Neoplasms | 2 | 1999 | 2097 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 620 | 0.070 |
Why?
| | Hypoglycemia | 1 | 2011 | 387 | 0.070 |
Why?
| | Combined Modality Therapy | 5 | 2021 | 1121 | 0.070 |
Why?
| | Interpersonal Relations | 1 | 2010 | 341 | 0.070 |
Why?
| | Research Design | 2 | 2011 | 928 | 0.070 |
Why?
| | Tissue Distribution | 1 | 2007 | 286 | 0.070 |
Why?
| | Skin Absorption | 1 | 2007 | 11 | 0.070 |
Why?
| | Cultural Characteristics | 1 | 2007 | 59 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2021 | 578 | 0.070 |
Why?
| | Receptors, Steroid | 1 | 2007 | 47 | 0.070 |
Why?
| | Tissue Donors | 1 | 2009 | 316 | 0.070 |
Why?
| | Administration, Topical | 1 | 2007 | 138 | 0.070 |
Why?
| | Proteins | 3 | 1989 | 908 | 0.070 |
Why?
| | Nerve Tissue Proteins | 2 | 2011 | 530 | 0.070 |
Why?
| | Asparaginase | 3 | 2001 | 31 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2009 | 444 | 0.070 |
Why?
| | Relaxin | 2 | 1998 | 15 | 0.070 |
Why?
| | Age Distribution | 2 | 2004 | 342 | 0.070 |
Why?
| | Spouses | 1 | 2007 | 85 | 0.060 |
Why?
| | Phosphorylation | 2 | 2021 | 1569 | 0.060 |
Why?
| | Gonadal Hormones | 1 | 2005 | 6 | 0.060 |
Why?
| | Anorexia Nervosa | 1 | 2006 | 64 | 0.060 |
Why?
| | Population Surveillance | 1 | 2008 | 392 | 0.060 |
Why?
| | Preoptic Area | 1 | 2005 | 5 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 1 | 2014 | 1003 | 0.060 |
Why?
| | Inhibin-beta Subunits | 1 | 2005 | 5 | 0.060 |
Why?
| | Phenotype | 3 | 2018 | 2797 | 0.060 |
Why?
| | Maternal Age | 2 | 2022 | 117 | 0.060 |
Why?
| | Internet | 2 | 2015 | 596 | 0.060 |
Why?
| | Libido | 1 | 2005 | 24 | 0.060 |
Why?
| | Interleukin-1 | 1 | 2009 | 966 | 0.060 |
Why?
| | Nuclear Proteins | 3 | 2022 | 591 | 0.060 |
Why?
| | Health Services Misuse | 1 | 2005 | 36 | 0.060 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 234 | 0.060 |
Why?
| | Blastomeres | 1 | 2004 | 12 | 0.060 |
Why?
| | Absorptiometry, Photon | 3 | 2015 | 224 | 0.060 |
Why?
| | Mass Screening | 1 | 2011 | 1006 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2017 | 482 | 0.060 |
Why?
| | Sex Characteristics | 3 | 2019 | 641 | 0.060 |
Why?
| | Vulnerable Populations | 1 | 2005 | 134 | 0.060 |
Why?
| | Infusions, Intravenous | 3 | 1994 | 371 | 0.060 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 98 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1075 | 0.060 |
Why?
| | Apoptosis | 2 | 2017 | 2363 | 0.060 |
Why?
| | Bone Marrow | 1 | 2005 | 244 | 0.060 |
Why?
| | Mutation | 2 | 2009 | 3346 | 0.060 |
Why?
| | Central Nervous System | 1 | 2005 | 235 | 0.060 |
Why?
| | Glutamic Acid | 1 | 2005 | 211 | 0.050 |
Why?
| | Minority Groups | 1 | 2005 | 227 | 0.050 |
Why?
| | MicroRNAs | 1 | 2009 | 600 | 0.050 |
Why?
| | Fetal Macrosomia | 1 | 2024 | 58 | 0.050 |
Why?
| | Elasticity | 2 | 2016 | 189 | 0.050 |
Why?
| | Contraceptives, Oral | 1 | 2003 | 25 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2023 | 106 | 0.050 |
Why?
| | Sugars | 1 | 2023 | 29 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 923 | 0.050 |
Why?
| | Melphalan | 2 | 1999 | 29 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2286 | 0.050 |
Why?
| | Remission Induction | 4 | 2009 | 233 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 2022 | 16 | 0.050 |
Why?
| | Follicular Atresia | 1 | 2002 | 4 | 0.050 |
Why?
| | Whole-Body Irradiation | 2 | 1999 | 73 | 0.050 |
Why?
| | alpha-Amylases | 1 | 2022 | 16 | 0.050 |
Why?
| | Receptors, Estrogen | 1 | 2004 | 372 | 0.050 |
Why?
| | Thyroid Hormones | 1 | 2022 | 53 | 0.050 |
Why?
| | Blood Pressure | 3 | 2017 | 1538 | 0.050 |
Why?
| | Snoring | 1 | 2021 | 12 | 0.050 |
Why?
| | Hypertension | 1 | 2010 | 1056 | 0.050 |
Why?
| | Breast | 1 | 2022 | 139 | 0.050 |
Why?
| | Preconception Care | 1 | 2022 | 31 | 0.050 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 24 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2022 | 81 | 0.050 |
Why?
| | Computers | 2 | 2000 | 60 | 0.050 |
Why?
| | Maternal-Child Nursing | 1 | 2001 | 9 | 0.050 |
Why?
| | Nursing Methodology Research | 1 | 2001 | 38 | 0.050 |
Why?
| | Canada | 1 | 2022 | 322 | 0.050 |
Why?
| | Prevotella | 1 | 2021 | 12 | 0.050 |
Why?
| | Open Reading Frames | 1 | 2021 | 117 | 0.050 |
Why?
| | Grief | 1 | 2001 | 35 | 0.050 |
Why?
| | Gestational Age | 1 | 2024 | 760 | 0.050 |
Why?
| | X Chromosome | 1 | 2001 | 47 | 0.050 |
Why?
| | Heparin | 1 | 2022 | 224 | 0.050 |
Why?
| | Reproducibility of Results | 3 | 2018 | 2766 | 0.050 |
Why?
| | Radiography | 2 | 2014 | 812 | 0.050 |
Why?
| | Anger | 1 | 2001 | 55 | 0.050 |
Why?
| | Pulmonary Blastoma | 1 | 2000 | 8 | 0.040 |
Why?
| | Body Surface Area | 1 | 2020 | 27 | 0.040 |
Why?
| | Pleural Neoplasms | 1 | 2000 | 18 | 0.040 |
Why?
| | Insemination | 1 | 2020 | 1 | 0.040 |
Why?
| | Illinois | 1 | 2020 | 37 | 0.040 |
Why?
| | Gestures | 1 | 2020 | 3 | 0.040 |
Why?
| | Chicago | 1 | 2020 | 45 | 0.040 |
Why?
| | Paper | 1 | 2000 | 8 | 0.040 |
Why?
| | Blood Volume | 1 | 2020 | 59 | 0.040 |
Why?
| | Cell Line | 2 | 2021 | 2637 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2014 | 811 | 0.040 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 1999 | 7 | 0.040 |
Why?
| | Sex Factors | 2 | 2019 | 1715 | 0.040 |
Why?
| | Personal Autonomy | 1 | 2000 | 39 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 236 | 0.040 |
Why?
| | Observer Variation | 1 | 2000 | 296 | 0.040 |
Why?
| | Focus Groups | 1 | 2021 | 383 | 0.040 |
Why?
| | Thrombin | 1 | 2000 | 139 | 0.040 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 1999 | 68 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 758 | 0.040 |
Why?
| | Sexual Maturation | 1 | 2019 | 47 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 1695 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 268 | 0.040 |
Why?
| | Triglycerides | 2 | 2017 | 467 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 387 | 0.040 |
Why?
| | Neurons | 1 | 2007 | 1280 | 0.040 |
Why?
| | Diet | 2 | 2023 | 1080 | 0.040 |
Why?
| | Gene Deletion | 1 | 2001 | 356 | 0.040 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 1999 | 5 | 0.040 |
Why?
| | Educational Status | 2 | 2012 | 412 | 0.040 |
Why?
| | Chromosome Breakage | 1 | 1999 | 21 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 399 | 0.040 |
Why?
| | Pregnant Women | 1 | 2000 | 131 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1999 | 43 | 0.040 |
Why?
| | Needs Assessment | 1 | 2001 | 315 | 0.040 |
Why?
| | Chromosome Inversion | 1 | 1999 | 17 | 0.040 |
Why?
| | Insurance, Health | 1 | 2001 | 244 | 0.040 |
Why?
| | Italy | 3 | 2009 | 92 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 485 | 0.040 |
Why?
| | Hyperthyroidism | 1 | 2018 | 26 | 0.040 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 196 | 0.040 |
Why?
| | Injections, Intravenous | 2 | 1990 | 198 | 0.040 |
Why?
| | Microinjections | 1 | 1998 | 76 | 0.040 |
Why?
| | Diagnostic Techniques, Obstetrical and Gynecological | 2 | 2008 | 6 | 0.040 |
Why?
| | Organ Size | 2 | 2010 | 436 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2019 | 125 | 0.040 |
Why?
| | Islets of Langerhans | 1 | 2004 | 728 | 0.040 |
Why?
| | Glucuronates | 1 | 2017 | 4 | 0.040 |
Why?
| | Conservative Treatment | 1 | 2018 | 29 | 0.040 |
Why?
| | Public Health | 1 | 2022 | 434 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2021 | 460 | 0.040 |
Why?
| | Cholesterol | 1 | 2019 | 367 | 0.040 |
Why?
| | Transaminases | 1 | 2017 | 24 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2540 | 0.040 |
Why?
| | Thrombosis | 1 | 2000 | 298 | 0.040 |
Why?
| | Mice | 4 | 2021 | 14872 | 0.040 |
Why?
| | Receptors, Angiotensin | 1 | 1997 | 9 | 0.040 |
Why?
| | Disease-Free Survival | 4 | 2001 | 620 | 0.040 |
Why?
| | Immunologic Tests | 1 | 1997 | 16 | 0.040 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 65 | 0.040 |
Why?
| | Pregnancy Tests | 1 | 2017 | 7 | 0.040 |
Why?
| | Vehicle Emissions | 1 | 2017 | 48 | 0.030 |
Why?
| | Biopsy | 1 | 2000 | 1036 | 0.030 |
Why?
| | Biological Assay | 1 | 2017 | 112 | 0.030 |
Why?
| | Hypertriglyceridemia | 1 | 2017 | 34 | 0.030 |
Why?
| | Qualitative Research | 1 | 2021 | 936 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2022 | 731 | 0.030 |
Why?
| | Genes | 1 | 1997 | 223 | 0.030 |
Why?
| | Molecular Weight | 3 | 2013 | 331 | 0.030 |
Why?
| | Hepatitis C | 2 | 2011 | 219 | 0.030 |
Why?
| | Transdermal Patch | 1 | 2016 | 15 | 0.030 |
Why?
| | Hyperprolactinemia | 1 | 2016 | 4 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2001 | 573 | 0.030 |
Why?
| | Alcohol Drinking | 2 | 2012 | 652 | 0.030 |
Why?
| | Galvanic Skin Response | 1 | 2016 | 26 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 360 | 0.030 |
Why?
| | Goiter | 1 | 1996 | 3 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 2 | 2008 | 99 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 480 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 726 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1320 | 0.030 |
Why?
| | Serologic Tests | 1 | 2015 | 49 | 0.030 |
Why?
| | Catheters, Indwelling | 2 | 1993 | 79 | 0.030 |
Why?
| | Hypothyroidism | 1 | 1996 | 64 | 0.030 |
Why?
| | Neuroblastoma | 1 | 1996 | 133 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 385 | 0.030 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 1995 | 35 | 0.030 |
Why?
| | Registries | 2 | 2020 | 1768 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1264 | 0.030 |
Why?
| | Cranial Irradiation | 2 | 2009 | 66 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 913 | 0.030 |
Why?
| | Peptide Fragments | 1 | 1999 | 666 | 0.030 |
Why?
| | Genetic Markers | 2 | 2011 | 320 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2016 | 173 | 0.030 |
Why?
| | Cyclosporine | 1 | 1995 | 161 | 0.030 |
Why?
| | Vincristine | 3 | 2001 | 98 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1342 | 0.030 |
Why?
| | Deafness | 1 | 1996 | 78 | 0.030 |
Why?
| | Certolizumab Pegol | 1 | 2014 | 3 | 0.030 |
Why?
| | Air Pollutants | 1 | 2017 | 242 | 0.030 |
Why?
| | Etanercept | 1 | 2014 | 51 | 0.030 |
Why?
| | Adalimumab | 1 | 2014 | 44 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 1994 | 173 | 0.030 |
Why?
| | Freezing | 1 | 1994 | 84 | 0.030 |
Why?
| | Glycerol | 1 | 1994 | 84 | 0.030 |
Why?
| | Drug Stability | 1 | 1994 | 151 | 0.030 |
Why?
| | Infliximab | 1 | 2014 | 94 | 0.030 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2014 | 69 | 0.030 |
Why?
| | Anions | 1 | 2013 | 30 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2014 | 140 | 0.030 |
Why?
| | Medical Records | 1 | 2014 | 153 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 796 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2013 | 135 | 0.030 |
Why?
| | Electrocardiography | 1 | 2016 | 560 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1997 | 695 | 0.030 |
Why?
| | Cell Survival | 2 | 2007 | 1021 | 0.030 |
Why?
| | Anal Canal | 1 | 1993 | 84 | 0.030 |
Why?
| | Menstruation-Inducing Agents | 1 | 2012 | 1 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2014 | 134 | 0.030 |
Why?
| | Postoperative Complications | 2 | 2001 | 2128 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 121 | 0.020 |
Why?
| | Tea | 1 | 2012 | 10 | 0.020 |
Why?
| | Growth Differentiation Factor 9 | 1 | 2011 | 4 | 0.020 |
Why?
| | Coffee | 1 | 2012 | 10 | 0.020 |
Why?
| | Pituitary Gland, Anterior | 1 | 2011 | 39 | 0.020 |
Why?
| | Alcoholic Beverages | 1 | 2012 | 17 | 0.020 |
Why?
| | Oogenesis | 1 | 2011 | 25 | 0.020 |
Why?
| | Women | 1 | 2012 | 51 | 0.020 |
Why?
| | Cystocele | 1 | 2011 | 1 | 0.020 |
Why?
| | Rectocele | 1 | 2011 | 2 | 0.020 |
Why?
| | Placentation | 1 | 2011 | 40 | 0.020 |
Why?
| | Fetal Death | 1 | 2011 | 50 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Ulna Fractures | 1 | 2011 | 13 | 0.020 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2011 | 15 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 180 | 0.020 |
Why?
| | Nerve Growth Factor | 1 | 2011 | 27 | 0.020 |
Why?
| | Colon | 1 | 1993 | 233 | 0.020 |
Why?
| | Receptor, trkB | 1 | 2011 | 28 | 0.020 |
Why?
| | Heterozygote | 1 | 2011 | 251 | 0.020 |
Why?
| | Progesterone Congeners | 1 | 2010 | 14 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2010 | 30 | 0.020 |
Why?
| | Radius Fractures | 1 | 2011 | 56 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 2010 | 162 | 0.020 |
Why?
| | Informed Consent | 1 | 2011 | 161 | 0.020 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2011 | 106 | 0.020 |
Why?
| | Survival Rate | 2 | 2009 | 1644 | 0.020 |
Why?
| | Cross Reactions | 1 | 2010 | 118 | 0.020 |
Why?
| | Dominica | 1 | 2010 | 1 | 0.020 |
Why?
| | Spinal Fractures | 1 | 2011 | 75 | 0.020 |
Why?
| | Proinsulin | 1 | 2010 | 48 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2001 | 1879 | 0.020 |
Why?
| | Daunorubicin | 2 | 2001 | 24 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 292 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2012 | 201 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4100 | 0.020 |
Why?
| | Hematology | 1 | 2009 | 13 | 0.020 |
Why?
| | Herpes Zoster | 1 | 2014 | 331 | 0.020 |
Why?
| | Ambulatory Care | 1 | 1993 | 478 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 663 | 0.020 |
Why?
| | Infusion Pumps | 1 | 1989 | 31 | 0.020 |
Why?
| | Pulse Therapy, Drug | 1 | 2009 | 6 | 0.020 |
Why?
| | Culture Techniques | 1 | 1989 | 78 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2009 | 60 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 561 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 1989 | 100 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2009 | 61 | 0.020 |
Why?
| | Prednisone | 2 | 2001 | 229 | 0.020 |
Why?
| | Polysomnography | 1 | 2009 | 136 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2009 | 77 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 181 | 0.020 |
Why?
| | Safety | 1 | 1990 | 298 | 0.020 |
Why?
| | West Indies | 1 | 2008 | 4 | 0.020 |
Why?
| | Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 3 | 0.020 |
Why?
| | Acid Phosphatase | 1 | 2008 | 17 | 0.020 |
Why?
| | Hyperhidrosis | 1 | 2008 | 5 | 0.020 |
Why?
| | RANK Ligand | 1 | 2008 | 26 | 0.020 |
Why?
| | Menorrhagia | 1 | 2008 | 14 | 0.020 |
Why?
| | Estrogen Antagonists | 1 | 2008 | 39 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2005 | 2219 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1579 | 0.020 |
Why?
| | Papio | 1 | 2008 | 96 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2000 | 2177 | 0.020 |
Why?
| | Pelvic Floor | 1 | 2008 | 22 | 0.020 |
Why?
| | Medical Oncology | 1 | 2009 | 229 | 0.020 |
Why?
| | Transplantation, Autologous | 2 | 1999 | 176 | 0.020 |
Why?
| | Collagen Type I | 1 | 2008 | 108 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2008 | 143 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 397 | 0.020 |
Why?
| | Isoenzymes | 1 | 2008 | 283 | 0.020 |
Why?
| | Microscopy, Immunoelectron | 1 | 2007 | 43 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 138 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 633 | 0.020 |
Why?
| | Obesity, Morbid | 1 | 2010 | 197 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2008 | 217 | 0.020 |
Why?
| | Transplantation Conditioning | 2 | 1999 | 151 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2014 | 927 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2007 | 133 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2011 | 927 | 0.020 |
Why?
| | Polymorphism, Genetic | 2 | 2000 | 610 | 0.020 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 52 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 808 | 0.020 |
Why?
| | New York | 1 | 2006 | 106 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 303 | 0.020 |
Why?
| | HIV-1 | 1 | 1991 | 768 | 0.020 |
Why?
| | Sleep Disorders, Intrinsic | 1 | 2005 | 1 | 0.020 |
Why?
| | Body Fluids | 1 | 1986 | 58 | 0.020 |
Why?
| | Placenta | 1 | 2011 | 628 | 0.020 |
Why?
| | Communication | 1 | 2011 | 744 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2011 | 2570 | 0.020 |
Why?
| | Microdialysis | 1 | 2005 | 49 | 0.020 |
Why?
| | Stroke | 1 | 2014 | 1022 | 0.020 |
Why?
| | Urban Population | 1 | 2008 | 397 | 0.020 |
Why?
| | Genomics | 1 | 2009 | 635 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2007 | 298 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2005 | 104 | 0.010 |
Why?
| | Demography | 1 | 2005 | 260 | 0.010 |
Why?
| | Life Change Events | 1 | 2005 | 135 | 0.010 |
Why?
| | Mutation, Missense | 1 | 2006 | 293 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2005 | 343 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 2003 | 2 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 848 | 0.010 |
Why?
| | Interviews as Topic | 1 | 2005 | 584 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1985 | 249 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 4694 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1551 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2005 | 395 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 3886 | 0.010 |
Why?
| | Calcium | 1 | 2007 | 1108 | 0.010 |
Why?
| | Estrus | 1 | 2001 | 11 | 0.010 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 13 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2000 | 57 | 0.010 |
Why?
| | Injections, Intramuscular | 1 | 2001 | 116 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2001 | 187 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1143 | 0.010 |
Why?
| | Random Allocation | 1 | 2001 | 335 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2000 | 274 | 0.010 |
Why?
| | Transplants | 1 | 1999 | 36 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2001 | 243 | 0.010 |
Why?
| | Consanguinity | 1 | 1999 | 46 | 0.010 |
Why?
| | Mercaptopurine | 1 | 1998 | 15 | 0.010 |
Why?
| | Thioguanine | 1 | 1998 | 19 | 0.010 |
Why?
| | Leucovorin | 1 | 1998 | 43 | 0.010 |
Why?
| | Cytarabine | 1 | 1998 | 51 | 0.010 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 1998 | 38 | 0.010 |
Why?
| | Pregnancy Trimester, Second | 1 | 1998 | 66 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 1998 | 79 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 294 | 0.010 |
Why?
| | Chromosome Aberrations | 1 | 1998 | 134 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1998 | 217 | 0.010 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 1997 | 7 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1997 | 77 | 0.010 |
Why?
| | Doxorubicin | 1 | 1998 | 285 | 0.010 |
Why?
| | Dexamethasone | 1 | 1998 | 317 | 0.010 |
Why?
| | Introns | 1 | 1997 | 227 | 0.010 |
Why?
| | Exons | 1 | 1997 | 302 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1987 | 318 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1997 | 522 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 1997 | 372 | 0.010 |
Why?
| | Risk | 1 | 1998 | 812 | 0.010 |
Why?
| | Syndrome | 1 | 1996 | 333 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1996 | 125 | 0.010 |
Why?
| | Drug Resistance | 1 | 1995 | 158 | 0.010 |
Why?
| | Recurrence | 1 | 1996 | 935 | 0.010 |
Why?
| | Liver Diseases | 1 | 1996 | 255 | 0.010 |
Why?
| | Colostomy | 1 | 1993 | 26 | 0.010 |
Why?
| | Testis | 1 | 1994 | 133 | 0.010 |
Why?
| | Base Sequence | 1 | 1997 | 2114 | 0.010 |
Why?
| | Anastomosis, Surgical | 1 | 1993 | 136 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2000 | 2087 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1997 | 2785 | 0.010 |
Why?
| | Lymphoma, AIDS-Related | 1 | 1991 | 13 | 0.010 |
Why?
| | Sarcoma, Kaposi | 1 | 1991 | 68 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1997 | 1313 | 0.010 |
Why?
| | Reoperation | 1 | 1993 | 514 | 0.010 |
Why?
| | Feedback | 1 | 1990 | 144 | 0.010 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1991 | 211 | 0.010 |
Why?
| | Equipment Contamination | 1 | 1989 | 54 | 0.010 |
Why?
| | Forearm | 1 | 1989 | 112 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1991 | 506 | 0.000 |
Why?
| | Bacterial Infections | 1 | 1989 | 218 | 0.000 |
Why?
| | Organ Culture Techniques | 1 | 1987 | 140 | 0.000 |
Why?
| | Isoelectric Point | 1 | 1986 | 22 | 0.000 |
Why?
| | Hemoglobins | 1 | 1986 | 315 | 0.000 |
Why?
| | Bacteria | 1 | 1989 | 725 | 0.000 |
Why?
|
|
Santoro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|